Danaher Corporation (LON:0R2B)
United Kingdom · Delayed Price · Currency is GBP · Price in USD | Market Cap | 122.84B +10.5% |
| Revenue (ttm) | 19.34B +5.5% |
| Net Income | 3.27B +23.6% |
| EPS | 4.55 +25.4% |
| Shares Out | n/a |
| PE Ratio | 38.05 |
| Forward PE | 25.59 |
| Dividend | 1.12 (0.65%) |
| Ex-Dividend Date | Sep 30, 2026 |
| Volume | 986 |
| Open | 231.00 |
| Previous Close | 230.69 |
| Day's Range | 230.00 - 238.00 |
| 52-Week Range | 159.95 - 244.50 |
| Beta | 0.80 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 21, 2026 |
About Danaher
Danaher Corporation designs, manufactures, and markets professional, medical, research, and industrial products and services in the United States, China, and internationally. The company operates through Biotechnology, Life Sciences, and Diagnostics segments. The Biotechnology segment provides technologies, consumables, services, and solutions that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufact... [Read more]
Financial Performance
In 2025, Danaher's revenue was $24.57 billion, an increase of 2.90% compared to the previous year's $23.88 billion. Earnings were $3.61 billion, a decrease of -7.31%.
Financial numbers in USD Financial StatementsNews
Danaher price target raised to $270 from $255 at BofA
BofA raised the firm’s price target on Danaher (DHR) to $270 from $255 and keeps a Buy rating on the shares. Management provided initial 2027 framing of 4%-5% core revenue…
Danaher price target raised to $270 from $255 at TD Cowen
TD Cowen raised the firm’s price target on Danaher (DHR) to $270 from $255 and keeps a Buy rating on the shares. The firm said the company’s new CEO Julie…
Danaher price target raised to $275 from $250 at Goldman Sachs
Goldman Sachs raised the firm’s price target on Danaher (DHR) to $275 from $250 and keeps a Buy rating on the shares.
Danaher price target raised to $270 from $250 at JPMorgan
JPMorgan raised the firm’s price target on Danaher (DHR) to $270 from $250 and keeps an Overweight rating on the shares.
Danaher price target raised to $260 from $220 at Stifel
Stifel raised the firm’s price target on Danaher (DHR) to $260 from $220 and keeps a Buy rating on the shares. Non-respiratory core growth came in a bit above expectations…
Danaher price target raised to $254 from $246 at Baird
Baird raised the firm’s price target on Danaher (DHR) to $254 from $246 and keeps an Outperform rating on the shares. The firm updated its model following Q3 results. Published…
Danaher price target raised to $270 from $230 at Citi
Citi analyst Patrick Donnelly raised the firm’s price target on Danaher (DHR) to $270 from $230 and keeps a Buy rating on the shares following the Q3 report. The firm…
Danaher price target raised to $260 from $255 at Barclays
Barclays raised the firm’s price target on Danaher (DHR) to $260 from $255 and keeps an Overweight rating on the shares following the Q3 report. The firm sees “plenty of…
Danaher Earnings Call Transcript: Q3 2026
Q3 sales were $6.6B, with core growth of 5.5% excluding respiratory revenue and adjusted EPS of $2.11. FY26 EPS guidance rose; 2027 core growth starts at 4%-5% excluding respiratory revenue, alongside a renewed focus on execution, innovation, and disciplined investment.
Danaher Quarterly report: Q3 2026
Danaher has published its Q3 2026 quarterly earnings report on October 21, 2026.
Danaher Slides: Q3 2026
Danaher has posted slides in relation to its Q3 2026 quarterly earnings report, which was published on October 21, 2026.
Danaher Earnings release: Q3 2026
Danaher released its Q3 2026 earnings on October 21, 2026, summarizing the period's financial results.
Danaher raises FY26 adjusted EPS view to $8.57-$9.62 from $8.45-$8.60
Consensus $8.51. The company said, “For full year 2026, the Company is increasing its full year adjusted diluted net earnings per common share guidance to a range of $8.57 to…
Danaher reports Q3 adjusted EPS $2.11, consensus $1.92
Reports Q3 revenue $6.55B, consensus $6.56B. Julie Sawyer Montgomery, president and CEO, stated, “We delivered better-than-expected third quarter revenue, earnings and cash flow, and are encouraged by...
Danaher sees Q4 core revenue up 4%-5%
Sawyer Montgomery continued, “Danaher (DHR) has built a strong foundation, and the time I’ve spent with our teams and customers during my transition into the CEO role has only reinforced…
Danaher Reports Third Quarter 2026 Results
WASHINGTON, Oct. 21, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) today announced results for the third quarter 2026. All results in this release reflect only continuing operations and period...
8 Stocks That Are Much Riskier Plays Than They Look
Some low beta stocks are more volatile on big down days for the market, including RTX, Charles Schwab, Union Pacific, Danaher, and Starbucks.
Danaher collaborates with Nvidia to advance autonomous science
Danaher (DHR) announced a collaboration with Nvidia (NVDA) to advance autonomous science and help accelerate the pace of scientific discovery. As part of Danaher’s broader effort to shape the future…
Danaher Collaborates with NVIDIA to Advance Autonomous Science
Collaboration will bring together NVIDIA AI technologies and Danaher's scientific instruments, laboratory workflows and data WASHINGTON, Oct. 14, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) t...
Danaher price target raised to $255 from $236 at TD Cowen
TD Cowen analyst Dan Brennan raised the firm’s price target on Danaher (DHR) to $255 from $236 and keeps a Buy rating on the shares. The firm adjusted targets in…
Danaher Announces Appointments of Daniel Comas and Robert Hershberg to Board of Directors
WASHINGTON, Oct. 12, 2026 /PRNewswire/ -- Danaher Corporation (NYSE: DHR) ("Danaher" or "the Company") today announced the appointment of Daniel L. Comas and Robert Hershberg, M.D.
Danaher price target raised to $240 from $220 at Morgan Stanley
Morgan Stanley analyst Kallum Titchmarsh raised the firm’s price target on Danaher (DHR) to $240 from $220 and keeps an Overweight rating on the shares.
Danaher price target raised to $255 from $230 at BofA
BofA raised the firm’s price target on Danaher (DHR) to $255 from $230 and keeps a Buy rating on the shares. The life science tools sector has further re-rated since…
Life sciences firm Danaher to launch AI-powered autonomous research lab in 2027
Life sciences company Danaher said on Wednesday it plans to launch its first AI-powered autonomous research lab early next year to make drug discovery and development faster and more efficient.